用组合疗法克服肝癌中免疫检查点阻塞的抵抗:一起更强?
Wiebke Werner1, Maria Kuzminskaya1, Isabella Lurje1
1Department of Hepatology and Gastroenterology, Charité Universitaetsmedizin Berlin, Berlin, Germany.
Seminars in liver disease
|May 28, 2024
概括
原发性肝癌,包括肝细胞癌 (HCC) 和肝内胆管癌 (CCA),预后不佳. 本综述探讨了免疫抵抗机制和组合免疫疗法,以改善肝癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 原发性肝癌,主要是肝细胞癌 (HCC) 和肝内胆管癌 (CCA),是全球癌症死亡的主要原因.
- 虽然早期的疾病可以通过手术或移植治疗,但晚期需要全身疗法来改善生存率.
- 免疫疗法,特别是免疫检查点抑制剂 (ICI),已成为先进的HCC和CCA的第一线治疗方法,但反应率仍然有限.
研究的目的:
- 审查原发性肝癌中瘤免疫逃脱和抵抗的机制.
- 专注于瘤微环境在HCC和CCA免疫疗法耐药性的作用.
- 讨论肝癌ICI组合疗法的进展.
主要方法:
- 关于原发性肝癌,免疫疗法和瘤微环境的研究文献综述.
- 对HCC和CCA中抗性机制的分析.
- 评估当前和新兴的ICI组合策略.
主要成果:
- 初级肝癌通常表现为寒冷或免疫抑制的瘤微环境,导致ICI反应率较低.
- 了解HCC和CCA中的特定瘤微环境组成,对于克服耐药性至关重要.
- 涉及ICI的组合疗法与现有治疗方法 (例如,多酶抑制剂,化疗) 和新方法的组合疗法显示出有前途.
结论:
- 在原发性肝癌中克服免疫抵抗需要对瘤微环境有深入的了解.
- 组合免疫疗法有可能提高反应率,并诱导长期的抗瘤免疫力.
- 未来的战略应侧重于合理设计的组合疗法,以改善HCC和CCA患者的治疗结果.
相关概念视频
01:27Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Cytotoxic T Cells-mediated Immune Response
892
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
892